Drugs.com - Clinical Trials

Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...

Mar 18, 2025 - 01:11
 0
Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...
Read More

Tags:

Previous Article

Longévité : l'industrie cosmétique doit repenser son rapport à l'âge

Next Article

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Produ...

Related Posts

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Receives FDA Fast Track Designation ...

Feb 9, 2025  0

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

U.S. FDA Accepts Gilead’s New Drug Applications for Twi...

Feb 27, 2025  0

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025  0